Drug intelligence / Profile preview

samarium-153 hydroxyapatite

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intra-articular Injection

Overview

Samarium-153 hydroxyapatite (153Sm-HA) is a radiopharmaceutical used for radiation synovectomy. It consists of the beta-emitting radioisotope Samarium-153 incorporated into hydroxyapatite particles. The drug is administered via intra-articular injection, delivering localized radiation to the synovial membrane. This radiation aims to reduce inflammation and ablate hypertrophied synovial tissue, making it effective in treating conditions like hemophilic arthropathy and rheumatoid arthritis.

Other names: 153Sm-HA

Beyond the preview

Go deeper on samarium-153 hydroxyapatite.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on samarium-153 hydroxyapatite.

Explore the full profile